Visionary Breakthrough: Science Corporation's Chip Restores Sight and Gains EU Approval

TL;DR

• Science Corporation’s PRIMA retinal implant has received European approval, allowing commercialization for patients with advanced dry age-related macular degeneration.
• The device pairs a tiny under-retina chip with camera-enabled glasses to restore functional central vision, with clinical data showing many patients regained the ability to read letters, numbers, and words.
• CEO Max Hodak says the company now wants to build meaningful revenue from PRIMA to fund the next wave of vision-restoration advances.

Science Corporation’s vision-restoring chip has crossed a major regulatory threshold in Europe, marking one of the most significant milestones yet for brain-computer interface medicine. The company’s PRIMA system is now approved for commercial use in Europe for people with geographic atrophy, the advanced form of dry age-related macular degeneration that destroys central vision.

The approval matters not just because it opens a new market, but because it validates a device that has shown unusually strong results in clinical testing. In published trial data, many patients regained the ability to read letters, numbers, and words after implantation, a level of outcome that researchers and the company describe as functional central vision restoration.

What PRIMA is and how it works

PRIMA is a two-part visual prosthesis built to bypass damaged photoreceptors in the retina. A tiny photovoltaic implant is placed under the retina, while special glasses with a camera and infrared projector send visual information to the implant, which then stimulates surviving retinal cells.

The system is designed for patients whose central vision has been lost to advanced dry AMD, especially geographic atrophy. Unlike therapies that try to slow retinal decline, PRIMA aims to replace part of the missing visual function itself.

What the clinical data showed

The company’s European clinical study and related trial results reported that 80% of patients achieved meaningful improvements in visual acuity, while 84% reported the ability to read letters, numbers, and words again. The company also said there was no significant decline in remaining peripheral vision, and that serious adverse events were mostly limited to the first two months after surgery and largely resolved.

Science has described these findings as evidence that the implant can restore “functional central vision,” which is a crucial distinction: the goal is not to recreate normal eyesight, but to give patients enough usable sight to read and recognize shapes in daily life.

Why Europe’s approval is a big commercial step

The EU green light gives Science Corporation a path to begin selling PRIMA in Europe, with Germany positioned as an early launch market because of its clinical-trial infrastructure and early-access pathways for novel medical technologies. Reporting indicates the first procedures could begin soon after approval, with one source citing a possible September start.

The company had already submitted its application for a CE mark after positive preliminary results, and its own materials note that the European PRIMAvera study supported that submission.

Max Hodak’s revenue push

Max Hodak, Science Corporation’s founder and CEO, has framed PRIMA as more than a medical milestone: it is also the foundation for a business meant to finance future innovation. Recent reporting says the company is targeting substantial revenue from PRIMA to support further development of the platform and additional indications.

That commercial strategy comes after a major financing round. Science Corporation raised $230 million earlier in 2026, giving it the resources to push toward market entry and broader regulatory expansion.

What comes next

Science is already exploring additional uses for the PRIMA platform, including Stargardt disease and retinitis pigmentosa, two inherited retinal conditions that affect younger patients. The company is also pursuing U.S. regulatory progress, with reports indicating an FDA fast-track designation and an ongoing approval pathway.

For patients with severe central vision loss, the approval is a rare example of a device that does not merely preserve remaining sight but can restore a measurable degree of it. If early commercial rollout matches the trial results, PRIMA could become a defining product in the emerging field of retinal neuroprosthetics.

The bigger significance

PRIMA’s success suggests that prosthetic vision is moving from laboratory concept to real-world medical product. If Europe’s launch goes smoothly, Science Corporation could establish one of the first commercially available brain-computer interface therapies in medicine, while also setting the stage for a broader category of implanted vision-restoration devices.

AndroGuider Team

Articles written by the AndroGuider team. We try to make them thorough and informational while being easy to read.